Migration of iron-labeled KHYG-1 natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic resonance imaging

Cytotherapy

Volumn 14, Issue 6, 2012, Pages 743-751

  Mallett, Christiane L ^a,b   McFadden, Catherine ^a   Chen, Yuhua ^a   Foster, Paula J ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Immunotherapy; KHYG 1; Natural killer cells; Prostate cancer

Indexed keywords

IRON OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL FATE; CELL LABELING; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; IN VIVO STUDY; KHYG 1 NATURAL KILLER CELL; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL NOISE RATIO; SKIN TUMOR; SUBCUTANEOUS TUMOR;

EID: 84862217450     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2012.667874     Document Type: Article

References (44)

1. Brand JM, Meller B, Von Hof K, Luhm J, Bä h re M, Kirchner H, Frohn C. Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev. 2004;13:307-14. (Pubitemid 38738372)
2. Koehl U, S ör ensen J, Esser R, Zimmermann S, Gr ü ttner HP, Tonn T, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004;33:261-6. (Pubitemid 39446496)
3. iller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051-7.
4. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10:625-32.
5. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59:1781-9.
6. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98-107.
7. Farag SS, Caligiuri M.A. Human natural killer cell development and biology. Blood Rev. 2006;20:123-37. (Pubitemid 43786166)
8. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJK. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 2003; 24:603-9. (Pubitemid 37338529)
9. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010;59:1739-44.
10. Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, et al. TCGF (IL 2)-receptor inducing factor (s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol. 1985;134:1623-30. (Pubitemid 15130281)
11. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652-8. (Pubitemid 24133034)
12. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996;24:406-15. (Pubitemid 26098857)
13. Yagita M, Huang C, Umehara H, Matsuo Y, Tabata R, Miyake M, et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000;14:922-30. (Pubitemid 30235072)
14. Cheng M, Ma J, Chen Y, Zhang J, Zhao W, Wei H, et al. Establishment, characterization and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line. Cell Transplant. 2011;20:1731-46.
15. Tam YK, Martinson JA, Doligosa K, Klingemann HG. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy. 2003;5:259-72. (Pubitemid 37086771)
16. Jha P, Golovko D, Bains S, Hostetter D, Meier R, Wendland MF, Daldrup-Link HE. Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities. Cancer Res. 2010;70:6109-13.
17. Matera L, Galetto A, Bello M, Baiocco C, Chiappino I, Castellano G, et al. In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma. J Transl Med. 2006;4:49.
18. Melder RJ, Brownell AL, Shoup TM, Brownell GL, Jain RK. Imaging of activated natural killer cells in mice by positron emission tomography: preferential uptake in tumors. Cancer Res. 1993;53:5867-71. (Pubitemid 24006151)
19. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-J Hematother Stem Cell Res. 2001;10:535-44. (Pubitemid 32756192)
20. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S, et al. In vivo tracking of genetically engineered, antiher2/ neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol. 2005;15:4-13. (Pubitemid 40109763)
21. Meier R, Piert M, Piontek G, Rudelius M, Oostendorp RA, Senekowitsch-Schmidtke R, et al. Tracking of [18F]fdglabeled natural killer cells to HER2/neu-positive tumors. Nucl Med Biol. 2008;35:579-88.
22. T avri S, Jha P, Meier R, Henning TD, Mü ller T, Hostetter D, et al. Optical imaging of cellular immunotherapy against prostate cancer. Mol Imaging. 2009;8:15-26.
23. Lim YT, Cho MY, Noh YW, Chung JW, Chung BH. Nearinfrared emitting fl uorescent nanocrystals-labeled natural killer cells as a platform technology for the optical imaging of immunotherapeutic cells-based cancer therapy. Nanotechnology. 2009;20:475102.
24. Meier R, Golovko D, Tavri S, Henning TD, Knopp C, Piontek G, et al. Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging. Magn Reson Med. 2011;65:756-63.
25. Foster-Gareau P, Heyn C, Alejski A, Rutt BK. Imaging single mammalian cells with a 1.5 T clinical MRI scanner. Mag Reson Med. 2003;49:968-71. (Pubitemid 36523485)
26. Heyn C, Ronald JA, Mackenzie LT, MacDonald IC, Chambers AF, Rutt BK, Foster PJ. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Mag Reson Med. 2006;55:23-9. (Pubitemid 43062924)
27. Shapiro EM, Sharer K, Skrtic S, Koretsky AP. In vivo detection of single cells by MRI. Magn Reson Med. 2006;55:242-9. (Pubitemid 43238090)
28. Frank JA, Miller BR, Arbab AS, Zywicke HA, Jordan EK, Lewis BK, et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology. 2003;228:480-7. (Pubitemid 36910091)
29. Bernas LM, Foster PJ, Rutt BK. Imaging iron-loaded mouse glioma tumors with bssfp at 3 T. Mag Reson Med. 2010;64: 23-31.
30. Ramadan SS, Heyn C, MacKenzie LT, Chambers AF, Rutt BK, Foster PJ. Ex-vivo cellular MRI with b-ssfp: quantitative benefi ts of 3 T over 1.5 T. Mag Reson Mat Phys Biol Med. 2008;21:251-9.
31. Gonzalez-Lara LE, Xu X, Hofstetrova K, Pniak A, Brown A, Foster PJ. In vivo magnetic resonance imaging of spinal cord injury in the mouse. J Neurotra. 2009;26:753-62.
32. Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, Fahim S, Keating A. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol. 2005;33:1160-71. (Pubitemid 41416964)
33. Kozlowski JM, Fidler IJ, Campbell D, Xu Z, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 1984;44:3522-9. (Pubitemid 14098607)
34. Rosset A, Spadola L, Ratib O. Osirix: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging. 2004;17:205-16. (Pubitemid 40378992)
35. McFadden C, Mallett CL, Foster PJ. Labeling of multiple cell lines using a new iron oxide agent for cell tracking by MRI. Cont Media Mol Imag. 2011;6:514-22.
36. M ül ler T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, et al. Expression of a CD20-specifi c chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother. 2008;57:411-23. (Pubitemid 350295385)
37. Suck G, Branch DR, Keating A. Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line. Int J Radiat Biol. 2006;82:355-61. (Pubitemid 43932713)
38. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate S.R. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 2004;114:560-568. (Pubitemid 39572106)
39. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med. 1991;174:479-88.
40. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43. (Pubitemid 43048949)
41. Petersen CC, Petersen MS, Agger R, Hokland ME. Accumulation in tumor tissue of adoptively transferred T cells: a comparison between intravenous and intraperitoneal injection. J Immunother. 2006;29:241-9. (Pubitemid 44297292)
42. Heyn C, Bowen CV, Rutt BK, Foster PJ. Detection threshold of single spio-labeled cells with FIESTA. Mag Reson Med. 2005;53:312-20. (Pubitemid 40171045)
43. Addicott B, Willman M, Rodriguez J, Padgett K, Han D, Berman D, et al. Mesenchymal stem cell labeling and in vitro MR characterization at 1.5 T of new SPIO contrast agent: Molday ION rhodamine-b. Cont Media Mol Imag. 2011;6:7-18.
44. Rohani R, de Chickera SN, Willert C, Chen Y, Dekaban GA, Foster PJ. In vivo cellular MRI of dendritic cell migration using micrometer-sized iron oxide (MPIO) particles. Mol Imaging Biol. 2011;13:679-94.